Bronchopulmonary dysplasia (BPD) is a common complication of prematurity, affecting 20% to 75% of infants born before gestational age (GA) 29 weeks.
1-3 BPD is associated with delayed brain maturation and diffuse white matter anomalies that are associated with increased risk of neurodevelopmental impairment.
4-6 Postnatal corticosteroids have been used to prevent and treat BPD for more than 50 years in multiple trials involving thousands of infants.
7-9 Dexamethasone, a long-acting glucocorticoid agonist, is 1 of the top 20 medications used in extremely preterm infants,
10,11 primarily to prevent or treat developing BPD. Multiple small trials and meta-analyses have demonstrated that short courses of low-dose dexamethasone may be useful for earlier weaning and extubation of infants undergoing mechanical ventilation at highest risk of BPD.
8,9,12 However, the administration of dexamethasone to prevent BPD, especially in the first week of life, has been associated with increased risk for adverse effects, including cognitive, speech, and learning impairments, as well as cerebral palsy (CP).
13-25 Routine dexamethasone therapy in the first week of life is not recommended.
26-28 Currently, most clinicians prescribe low-dose, late-initiated dexamethasone
29 of shorter duration than what was previously used
28,30 to maximize benefits and minimize potential risks. Prednisolone and methylprednisolone are synthetic glucocorticoids with similar potency that are used interchangeably in practice to prevent or treat BPD. Their effectiveness has only been evaluated retrospectively.
31,32